Gene and cell therapy success
Oxford BioMedica annual report 2013
Oxford BioMedica has strong fundamentals as an investment proposition. They have a valuable and focused pipeline of gene therapy products in development, addressing ophthalmology, central nervous system disorders and oncology. This annual report explains how using gene and cell therapy is closer than ever to becoming mainstream treatment in healthcare world-wide.